Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Cleveland BioLabs stock

Learn how to easily invest in Cleveland BioLabs stock.

Cleveland BioLabs Inc is a biotechnology business based in the US. Cleveland BioLabs shares (CBLI) are listed on the NASDAQ and all prices are listed in US Dollars. Cleveland BioLabs employs 18 staff and has a trailing 12-month revenue of around $106,900.

How to buy shares in Cleveland BioLabs

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CBLI – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Cleveland BioLabs stock price (NASDAQ: CBLI)

Use our graph to track the performance of CBLI stocks over time.

Cleveland BioLabs shares at a glance

Information last updated 2021-12-26.
52-week range$2.11 - $4.04
50-day moving average $3.62
200-day moving average $3.62
Wall St. target price$2.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.74

Buy Cleveland BioLabs shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, ETFs, Cryptocurrency
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Stocks, ETFs, Cryptocurrency
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Cleveland BioLabs stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cleveland BioLabs price performance over time

Historical closes compared with the close of $N/A from 2021-12-01

1 week (2022-09-24) N/A
1 month (2022-09-01) N/A
3 months (2022-07-01) N/A
6 months (2022-04-01) N/A
1 year (2021-10-05) -100.00%
2 years (2020-10-05) -100.00%
3 years (2019-10-04) -100.00%
5 years (2017-10-05) -100.00%

Cleveland BioLabs financials

Revenue TTM $106,900
Gross profit TTM $-428,128
Return on assets TTM -20.33%
Return on equity TTM -31.86%
Profit margin 0%
Book value $0.60
Market capitalisation $49.1 million

TTM: trailing 12 months

Cleveland BioLabs share dividends

We're not expecting Cleveland BioLabs to pay a dividend over the next 12 months.

Have Cleveland BioLabs's shares ever split?

Cleveland BioLabs's shares were split on a 1:20 basis on 27 January 2015. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cleveland BioLabs shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Cleveland BioLabs shares which in turn could have impacted Cleveland BioLabs's share price.

Cleveland BioLabs share price volatility

Over the last 12 months, Cleveland BioLabs's shares have ranged in value from as little as $2.11 up to $4.04. A popular way to gauge a stock's volatility is its "beta".

CBLI.US volatility(beta: 0.68)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cleveland BioLabs's is 0.6837. This would suggest that Cleveland BioLabs's shares are less volatile than average (for this exchange).

Cleveland BioLabs overview

Cytocom, Inc. , a clinical-stage biopharmaceutical company, develops novel small molecule immunotherapies targeting cancer, autoimmune, inflammatory, and infectious diseases. Its platform, Advanced Immunomodulating Multi-receptor System (AIMS), offers noroxymorphone analogs multi-receptor modulating therapies and proenkephalin analogs multi-receptor modulating therapies. The company also has various clinical-stage development programs, including CYTO-200 for Crohn's disease, fibromyalgia, multiple sclerosis, and covid-19; CYTO-400 for hepatocellular and pancreatic cancer; and CYTO-600 for acute radiation syndrome, advanced solid tumors, and vaccine adjuvant. Cytocom, Inc. has a collaboration agreement with the La Jolla Institute for Immunology for research and development of new immune-modulating agents targeting toll-like receptors for the treatment of cancer, infectious, autoimmune, and chronic inflammatory diseases. The company is based in Fort Collins, Colorado.

Frequently asked questions

What percentage of Cleveland BioLabs is owned by insiders or institutions?
Currently 52.548% of Cleveland BioLabs shares are held by insiders and 4.774% by institutions.
How many people work for Cleveland BioLabs?
Latest data suggests 18 work at Cleveland BioLabs.
When does the fiscal year end for Cleveland BioLabs?
Cleveland BioLabs's fiscal year ends in December.
Where is Cleveland BioLabs based?
Cleveland BioLabs's address is: 2537 Research Boulevard, Fort Collins, CO, United States, 80526
What is Cleveland BioLabs's ISIN number?
Cleveland BioLabs's international securities identification number is: US8575611046
What is Cleveland BioLabs's CUSIP number?
Cleveland BioLabs's Committee on Uniform Securities Identification Procedures number is: 185860103

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site